We are live on
!
Find out more
IHM
Iguana Healthcare Management Portfolio holdings
AUM
$152M
1-Year Est. Return
48.74%
This Fund
S&P 500
This Quarter
Est. Return
+23.92%
1 Year Est. Return
+48.74%
3 Year Est. Return
+142.13%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$238M
AUM Growth
+$30.8M
(+15%)
Cap. Flow
+$7.19M
Cap. Flow
% of AUM
3.03%
Top 10 Holdings %
Top 10 Hldgs %
44.18%
Holding
90
New
31
Increased
11
Reduced
13
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$17.6M |
| 2 |
AGN
Allergan plc
AGN
|
+$7.13M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$6.94M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$6.03M |
| 5 |
ESRX
Express Scripts Holding Company
ESRX
|
+$5.03M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$13.6M |
| 2 |
Medtronic
MDT
|
+$9.03M |
| 3 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$6.13M |
| 4 |
Viatris
VTRS
|
+$5.64M |
| 5 |
Amgen
AMGN
|
+$5.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.93% |
| 2 | Real Estate | 0.91% |
| 3 | Technology | 0.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pfizer
PFE
$149B
| $20.9M | 8.78% |
632,400
+553,350
| +700% | +$17.6M |
|
|
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
| $18.5M | 7.79% |
200,000
| – | – |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $12.7M | 5.33% |
110,000
| – | – |
|
|
4
Ultragenyx Pharmaceutical
RARE
$2.54B
| $10.9M | 4.57% |
175,000
+125,000
| +250% | +$6.94M |
|
5
Gilead Sciences
GILD
$162B
| $9.81M | 4.13% |
100,000
-25,000
| -20% | -$2.54M |
|
|
AGN
6
DELISTED
Allergan plc
AGN
| $7.44M | 3.13% |
+25,000
| New | +$7.13M |
|
|
XLRN
7
DELISTED
Acceleron Pharma
XLRN
| $6.66M | 2.8% |
175,000
-40,000
| -19% | -$1.59M |
|
|
8
iShares Russell 2000 ETF
IWM
$82.1B
| $6.22M | 2.62% |
+50,000
| New | +$6.03M |
|
9
Supernus Pharmaceuticals
SUPN
$2.72B
| $6.04M | 2.54% |
500,000
| – | – |
|
10
Puma Biotechnology
PBYI
$413M
| $5.9M | 2.48% |
25,000
+15,000
| +150% | +$3.21M |
|
11
Zimmer Biomet
ZBH
$18.8B
| $5.88M | 2.47% |
51,500
+25,750
| +100% | +$2.94M |
|
|
AXDX
12
DELISTED
Accelerate Diagnostics
AXDX
| $5.63M | 2.37% |
25,000
+20,000
| +400% | +$4.18M |
|
|
ENDP
13
DELISTED
Endo International plc
ENDP
| $5.38M | 2.26% |
+60,000
| New | +$5.02M |
|
14
Humana
HUM
$44.1B
| $5.34M | 2.25% |
+30,000
| New | +$4.75M |
|
|
ESRX
15
DELISTED
Express Scripts Holding Company
ESRX
| $5.21M | 2.19% |
+60,000
| New | +$5.03M |
|
|
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.19M | 2.18% |
200,000
| – | – |
|
|
STJ
17
DELISTED
St Jude Medical
STJ
| $4.91M | 2.06% |
+75,000
| New | +$4.99M |
|
|
GWPH
18
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $4.56M | 1.92% |
50,000
-10,000
| -17% | -$812K |
|
|
WCG
19
DELISTED
Wellcare Health Plans, Inc.
WCG
| $4.12M | 1.73% |
+45,000
| New | +$3.76M |
|
|
TRNX
20
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $3.93M | 1.65% |
150,000
| – | – |
|
21
Cigna
CI
$72.7B
| $3.88M | 1.63% |
+30,000
| New | +$3.49M |
|
|
AERI
22
DELISTED
Aerie Pharmaceuticals
AERI
| $3.76M | 1.58% |
120,000
-30,000
| -20% | -$870K |
|
23
Cardinal Health
CAH
$55.7B
| $3.61M | 1.52% |
+40,000
| New | +$3.44M |
|
|
IPXL
24
DELISTED
Impax Laboratories, Inc.
IPXL
| $3.52M | 1.48% |
75,000
-25,000
| -25% | -$995K |
|
|
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
| $3.46M | 1.46% |
500,000
+375,000
| +300% | +$3.6M |
|
Similar funds
HWP
PAM
USG2
LCM
FPF
FIAS
CII
OPWM
Iguana Healthcare Management's Q1 2015 Portfolio in Review
As of Q1 2015, Iguana Healthcare Management held 90 positions worth $238M, up 15% from $207M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Iguana Healthcare Management deployed $7.19M of net new capital in Q1 2015, opening 31 new positions and adding to 11 existing holdings. Its largest new stake was Allergan plc: 25,000 shares worth $7.44M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 71% a quarter earlier, followed by Real Estate and Technology.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2.54M trimmed.
- Iguana Healthcare Management's largest Q1 2015 buy was Allergan plc: 25,000 shares worth $7.44M.
- Iguana Healthcare Management added most to Pfizer in Q1 2015, an estimated $17.6M increase.
- Iguana Healthcare Management's biggest Q1 2015 reduction was Gilead Sciences, cutting an estimated $2.54M.
- Iguana Healthcare Management fully exited Biogen in Q1 2015, selling an estimated $13.6M.
- Iguana Healthcare Management's ten largest holdings make up 44% of its $238M portfolio in Q1 2015.
- Iguana Healthcare Management opened 31 new positions and closed 28 in Q1 2015.
- Iguana Healthcare Management's portfolio value rose 15% quarter-over-quarter to $238M.
Based on Iguana Healthcare Management's 13F filing for Q1 2015, filed 18 May 2015.